Eun Hyun Ahn , PhD
Email: ahneun@uw.edu
Dr. Ahn’s current research interests are focused on: Breast cancer stem cell mutagenesis and DNA repair and microenvironmental regulation of cancer stem cells and carcinogenesis. Dr.Ahn’s previous research areas include: (1) Identification and biochemical characterization of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma; (2) Regulation of differentiation of human mesenchymal stem cells and cardiac precursor cells by nanotopography-induced cellular stiffness and rigidity; (3) Roles of retinoic acids and retinoic acid receptorson proliferation, cell cycle, and cell signaling; (4) chemotherapeutic and chemopreventive mechanisms of sphingolipids in colon and breast cancers; Anti-tumorigenic activities of antisense oligonucleotides against AKT1 in various cancer cells.
Katie Albert , MD
Email: Katie.Albert@seattlechildrens.org
Dr. Albert's clinical interests are in pediatric oncology, pediatric sarcomas, pediatric solid tumors, adolescent and young adult oncology. Her research interests are molecular targets in sarcomas and immunotherapy for pediatric solid tumors.
Mike Averkiou , PhD
Email: maverk@uw.edu
Phone: (206) 616-9558
Dr. Averkiou develops new ultrasound imaging and therapy technology for disease detection, improved cancer treatment and monitoring, improved drug delivery to targeted cells, and heart disease. Using advanced nonlinear imaging techniques and microbubble contrast agents, he is able to detect the earliest stages of tumor angiogenesis and atherosclerosis, and closely monitor their treatment. He focuses on transferring innovations from preclinical research into clinical use.
Geoffrey Baird , MD, PhD
Email: gbaird@uw.edu
Phone: (206)744-9787
Dr. Baird's clinical interests include laboratory test utilization, molecular diagnostics, proteomics and immunohistochemistry. His group has developed a new proteomic technology for biomarker discovery in a range of diseases such as malignancies, cardiovascular disorders, and inflammatory conditions. One application of their technology is to discover protein expression changes associated with non-small cell lung cancer that have implications for diagnosis and treatment.
K. Scott Baker , MD
Email: ksbaker@fredhutch.org
Phone: (206) 667-5594
Dr. Baker is a pediatric oncologist. His main focus is on late effects of cancer therapy, in particular in patients that have undergone hematopoietic stem cell transplant for non-malignant disorders such as bone marrow failure syndromes, primary immunodeficiencies, and the histocytic disorders. He is interested in the use of umbilical cord blood for use in transplantation for both malignant and non-malignant diseases.
William Bensinger , MD
Email: wbensing@fredhutch.org
Phone: (206) 667-4933
Dr. Bensinger treats patients with multiple myeloma, amyloidosis, and plasmacytoma. His clinical interests are Autologous Stem Cell Transplantation, Immunotherapy and Targeted Radiotherapy.
Lynn Bonham , PhD
Email: lbonham@seattlecca.org
Phone: (206)288-2022
Dr. Bonham directs and manages Cellular Therapeutics at SCCA, which processes cells from peripheral blood, bone marrow and cord blood for standard transplantations and clinical trials for cancer treatment.
Roger Brent , PhD
Email: rbrent@fredhutch.org
Phone: (206) 667-1482
Dr. Brent studies the quantitative operation of the systems that living cells use to sense, represent, transmit, and act upon information to make decisions that determine their future fates. He specifically studies prototypic cell signaling systems in budding yeast and the pheromone response system; he has extended similar work to systems operating in single cells of tissues in a metazoan, Caenorhabditis elegans.
Mac Cheever , MD
Email: mcheever@fredhutch.org
Phone: (206) 667-4141
Dr. Cheever's specialty is in the areas of medical oncology, immunotherapy and solid tumor research. His current research interests are in conducting cancer clinical trials to develop and test new immunotherapies. He also interested on developing the principles of T cell therapy, cancer antigen discovery and development of cancer vaccines, especially for breast cancer.
Min Fang , MD, PhD
Email: fangm@uw.edu
Phone: (206) 288-1390
Dr. Fang's research focus is on the genomics and combinatorial genetics/epigenetics of human neoplasia. She is combining classical genetic approaches of mapping, karyotyping, and functional genetics with new genomic tools including microarray, comparative genome hybridization, and next-generation sequencing, to identify genetic and epigenetic aberrations in cancer that may serve as actionable biomarkers for treatment decision making for individual patients.
Manuel Ferreira , MD, PhD
Email: manuelf3@u.washington.edu
Phone: (206) 744-932
Dr. Ferreira specializes in the multi-modality treatment for tumors of the skull base, brain and spinal cord, including meningiomas; schwannomas; pituitary tumors; craniopharyngiomas; neurofibromatosis; chordomas and chondrosarcomas; Von Hippel-Lindau; hemangioblastomas; sinonasal tumors of the skull base; and cysts. He uses minimally-invasive skull base procedures to treat these conditions. Moreover he conducts research to understand the genetic basis of these tumors and inherited disorders and wants to use the genetic discovery to predict response to therapy (radio-sensitivity or radio-resistance).
Gary Goodman , MD, MS
Email: gary.goodman@swedish.org
Phone: (206) 667-5722
Dr. Goodman is specialized in internal medicine. His clinical interests are: General Medical Oncology, Lung Cancer, Melanoma, Ovarian Cancer, Renal Cell Cancer and Sarcoma.
Barry Gumbiner , PhD
Email: gumbiner@uw.edu
Phone: 206-884-5116
Dr. Gumbiner and his team study how cadherin cell adhesion molecules and associated catenin proteins control tumor development and progression. Cadherins and catenins play important roles in the morphogenesis, maintenance, and regeneration of tissues, and alterations in their functions are important in cancer. One major effort of the laboratory is to understand how cadherins signal into the cell to control growth and differentiation through regulation of both the Wnt-beta-catenin pathway and the Hippo signaling pathway; the latter inhibits cell proliferation and participates in organ size control. Cadherins mediate contact inhibition of growth by stimulating the Hippo pathway, while growth factors, such as EGF, inhibit the Hippo pathway. They are investigating how these modes of regulation of the Hippo pathway affect the development of different types of tumors. Another major effort of the laboratory is to understand how cadherin adhesive function at the cell surface is regulated to control tissue architecture and tumor cell invasion. Loss of E-cadherin expression associated with the epithelial-mesenchymal transition (EMT) is known to promote tumorigenesis and metastasis. However, many tumors and metastases retain E-cadherin expression, and they have found that instead it can be inactivated at the cell surface to cause the loss in function. They have generated a novel class of monoclonal antibodies that activate E-cadherin at the cell surface to restore its adhesive function, and are evaluating whether they reduce tumor invasion and metastasis in animal models. He and his team are also studying how catenins and cancer-associated mutations in E-cadherin affect its ability to switch to the active state and regulate tumor development. The mechanisms by which cadherins and catenins affect tumor growth are varied and complex and offer potential approaches for intervention.
Jared Harwood , MD, MBA
Email: harwoodj@uw.edu
Phone: (206) 221-4469
Dr. Harwood specializes in the evaluation and treatment of bone and soft tissue tumors of the extremities and pelvis and is well versed in general Orthopaedic care. His clinical interests include limb-sparing tumor resections and reconstructions, percutaneous osseointegrated prostheses, targeted muscle re-innervation, prophylactic treatment of metastatic disease, and revision joint replacement. His research interests include efficiency and sustainability of healthcare, opioid stewardship, process improvement, mentorship/leadership, communication, and outcomes in the treatment of metastatic disease.
Emily Hatch , PhD
Email: ehatch@fredhutch.org
Dr. Emily Hatch studies the structure and dynamics of the mammalian nuclear envelope (NE). Her goals are to understand the molecular mechanisms that initiate NE remodeling in interphase and how defects in NE stability impact cancer development and disease pathogenesis. Her approach combines imaging, biochemical, and genomic techniques with cell-based systems to understand how NE proteins are altered during interphase remodeling, the nuclear and cellular consequences of disrupting the NE barrier, and the long-term effects of NE disruption on cell proliferation and functioning.
Douglas Hawkins , MD
Email: doug.hawkins@seattlechildrens.org
Phone: (206) 987-2106
Dr. Hawkins treats pediatric and young adult oncology patients, with a special interest in Ewing's sarcoma, rhabdomyosarcoma, and osteosarcoma.
Rodney Ho , PhD
Email: Rodneyho@u.washington.edu
Phone: (206) 543-3796
Dr. Ho's research involves drug targeting and translational medicine. He has developed nanomedicine and device-enabled technologies that make anti-infective agents such as HIV, pain and cancer medications more effective and safe.
David Hockenbery , MD
Email: dhockenb@fredhutch.org
Phone: (206) 667-4611
Dr. Hockenbery specializes in gastroenterology and the genetic and biochemical mechanisms of apoptosis. Currently his group is focusing on: Investigation of the role of the c-myc transcription factor in bioenergetic regulation in cell growth and division, neoplastic transformation and apoptosis; Analysis of cell signaling and transcriptional responses to nutrient excess, employed in cells susceptible to neoplastic transformation.
Noah Hoffman , MD, PhD
Email: ngh2@uw.edu
Phone: (206) 598-7932
Dr. Hoffman's clinical interests and responsibilities include the development and application of software and processes for the collection, management, and display of data generated in the clinical laboratory. His research is focused on creating applications and algorithms to classify medically important microorganisms using biological sequence information.
Sara Javid , MD
Email: sjavid@u.washington.edu
Phone: (206) 221-2958
Dr. Javid is a surgical oncologist whose practice is concentrated in the diagnosis and treatment of breast cancer and benign breast disorders. She has clinical expertise in breast conserving surgery (lumpectomy, oncoplastic lumpectomy), sentinel lymph node biopsy, prophylactic mastectomy and nipple and skin-sparing mastectomy.